Oncternal Therapeutics is a biotechnology business based in the US. Oncternal Therapeutics shares (ONCT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.05 – a decrease of 15.75% over the previous week. Oncternal Therapeutics employs 27 staff and has a trailing 12-month revenue of around $1.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.05 |
|---|---|
| 52-week range | $1.05 - $13.20 |
| 50-day moving average | $3.04 |
| 200-day moving average | $7.10 |
| Wall St. target price | $20.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-11.42 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.05 from 2024-10-14
| 1 week (2024-10-08) | -15.75% |
|---|---|
| 1 month (2024-09-13) | -28.08% |
| 3 months (2024-07-15) | -86.31% |
| 6 months (2024-04-15) | -88.07% |
| 1 year (2023-10-13) | 250.00% |
|---|---|
| 2 years (2022-10-14) | -3.67% |
| 3 years (2021-10-15) | 3.87 |
| 5 years (2019-10-15) | 5.55 |
| Revenue TTM | $1.8 million |
|---|---|
| Gross profit TTM | $-31,490,000 |
| Return on assets TTM | -63.09% |
| Return on equity TTM | -118.06% |
| Profit margin | 0% |
| Book value | $5.32 |
| Market Capitalization | $3.3 million |
TTM: trailing 12 months
We're not expecting Oncternal Therapeutics to pay a dividend over the next 12 months.
Oncternal Therapeutics's shares were split on a 1:20 basis on 7 January 2024. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oncternal Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Oncternal Therapeutics shares which in turn could have impacted Oncternal Therapeutics's share price.
Over the last 12 months, Oncternal Therapeutics's shares have ranged in value from as little as $1.05 up to $13.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oncternal Therapeutics's is 1.358. This would suggest that Oncternal Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc. ; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.